Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 244
Filter
Add more filters

Publication year range
1.
Mycopathologia ; 189(4): 61, 2024 Jul 03.
Article in English | MEDLINE | ID: mdl-38958798

ABSTRACT

The genus Aspergillus consists of a vast number of medically and environmentally relevant species. Aspergillus species classified in series Versicolores are ubiquitous in the environment and include the opportunistic pathogen Aspergillus sydowii, which is associated with onychomycosis and superficial skin infections. Despite frequent clinical reports of A. sydowii and related series Versicolores species, antifungal susceptibility data are scarce, hampering optimal treatment choices and subsequent patient outcomes. Here, we employed antifungal susceptibility testing (AFST) based on microbroth dilution on a set of 155 series Versicolores strains using the common antifungals amphotericin B, itraconazole, voriconazole, posaconazole, isavuconazole and micafungin with the addition of luliconazole and olorofim. All strains were identified using partial calmodulin gene sequencing, with 145 being A. sydowii, seven A. creber and three A. versicolor, using the latest taxonomic insights. Overall, tested antifungals were potent against the entire strain collection. In comparison to A. fumigatus, azole and amphotericin B MICs were slightly elevated for some strains. AFST with luliconazole and olorofim, here reported for the first time, displayed the highest in vitro activity, making these antifungals interesting alternative drugs but clinical studies are warranted for future therapeutic use.


Subject(s)
Antifungal Agents , Aspergillosis , Aspergillus , Environmental Microbiology , Microbial Sensitivity Tests , Antifungal Agents/pharmacology , Aspergillus/drug effects , Aspergillus/classification , Aspergillus/isolation & purification , Humans , Aspergillosis/microbiology , Aspergillosis/drug therapy , Calmodulin/genetics , Sequence Analysis, DNA , Acetamides , Piperazines , Pyrimidines , Pyrroles
2.
Mycopathologia ; 189(1): 6, 2024 Jan 17.
Article in English | MEDLINE | ID: mdl-38231295

ABSTRACT

Madurella fahalii is a causative agent of the implantation mycosis mycetoma with decreased susceptibility to itraconazole, the preferred therapeutic drug to combat mycetoma. Here, we report the M. fahalii type-strain CBS 129176 genome assembly and annotation to identify a glutamic acid insert near the azole-binding pocket in the Cyp51A protein.


Subject(s)
Madurella , Mycetoma , Itraconazole/pharmacology , Azoles
3.
Mycopathologia ; 189(3): 43, 2024 May 06.
Article in English | MEDLINE | ID: mdl-38709328

ABSTRACT

During an epidemiological survey, a potential novel species within the basidiomycetous yeast genus Trichosporon was observed. The clinical strain was obtained from a urine sample taken from a Brazilian kidney transplant recipient. The strain was molecularly identified using the intergenic spacer (IGS1) ribosomal DNA locus and a subsequent phylogenetic analysis showed that multiple strains that were previously reported by other studies shared an identical IGS1-genotype most closely related to that of Trichosporon inkin. However, none of these studies provided an in-depth characterization of the involved strains to describe it as a new taxon. Here, we present the novel clinically relevant yeast for which we propose the name Trichosporon austroamericanum sp. nov. (holotype CBS H-24937). T. austroamericanum can be distinguished from other siblings in the genus Trichosporon using morphological, physiological, and phylogenetic characters.


Subject(s)
DNA, Fungal , DNA, Ribosomal Spacer , Phylogeny , Sequence Analysis, DNA , Transplant Recipients , Trichosporon , Trichosporonosis , Trichosporon/classification , Trichosporon/genetics , Trichosporon/isolation & purification , DNA, Ribosomal Spacer/genetics , DNA, Ribosomal Spacer/chemistry , DNA, Fungal/genetics , Humans , Brazil , Trichosporonosis/microbiology , Cluster Analysis , Mycological Typing Techniques , Kidney Transplantation , Microscopy , Genotype
4.
Mycopathologia ; 189(3): 44, 2024 May 11.
Article in English | MEDLINE | ID: mdl-38734862

ABSTRACT

A 50-year-old man, previously diagnosed with pulmonary tuberculosis and lung cavities, presented with symptoms including fever, shortness of breath, and cough. A pulmonary CT scan revealed multiple cavities, consolidation and tree-in-bud in the upper lungs. Further investigation through direct examination of bronchoalveolar lavage fluid showed septate hyphae with dichotomous acute branching. Subsequent isolation and morphological analysis identified the fungus as belonging to Aspergillus section Nigri. The patient was diagnosed with probable invasive pulmonary aspergillosis and successfully treated with a three-month oral voriconazole therapy. Phylogenetic analysis based on partial ß-tubulin, calmodulin and RNA polymerase second largest subunit sequences revealed that the isolate represents a putative new species related to Aspergillus brasiliensis, and is named Aspergillus hubkae here. Antifungal susceptibility testing demonstrated that the isolate is resistant to itraconazole but susceptible to voriconazole. This phenotypic and genetic characterization of A. hubkae, along with the associated case report, will serve as a valuable resource for future diagnoses of infections caused by this species. It will also contribute to more precise and effective patient management strategies in similar clinical scenarios.


Subject(s)
Antifungal Agents , Aspergillus , Invasive Pulmonary Aspergillosis , Microbial Sensitivity Tests , Phylogeny , Sequence Analysis, DNA , Voriconazole , Humans , Male , Middle Aged , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Aspergillus/isolation & purification , Aspergillus/genetics , Aspergillus/classification , Aspergillus/drug effects , Bronchoalveolar Lavage Fluid/microbiology , Cluster Analysis , DNA, Fungal/genetics , DNA, Fungal/chemistry , Invasive Pulmonary Aspergillosis/microbiology , Invasive Pulmonary Aspergillosis/drug therapy , Invasive Pulmonary Aspergillosis/diagnosis , Itraconazole/pharmacology , Microscopy , Tomography, X-Ray Computed , Treatment Outcome , Tubulin/genetics , Voriconazole/therapeutic use , Voriconazole/pharmacology
5.
Clin Microbiol Rev ; 35(4): e0023321, 2022 12 21.
Article in English | MEDLINE | ID: mdl-36074014

ABSTRACT

Paracoccidioidomycosis (PCM), initially reported in 1908 in the city of São Paulo, Brazil, by Adolpho Lutz, is primarily a systemic and neglected tropical mycosis that may affect individuals with certain risk factors around Latin America, especially Brazil. Paracoccidioides brasiliensis sensu stricto, a classical thermodimorphic fungus associated with PCM, was long considered to represent a monotypic taxon. However, advances in molecular taxonomy revealed several cryptic species, including Paracoccidioides americana, P. restrepiensis, P. venezuelensis, and P. lutzii, that show a preference for skin and mucous membranes, lymph nodes, and respiratory organs but can also affect many other organs. The classical diagnosis of PCM benefits from direct microscopy culture-based, biochemical, and immunological assays in a general microbiology laboratory practice providing a generic identification of the agents. However, molecular assays should be employed to identify Paracoccidioides isolates to the species level, data that would be complemented by epidemiological investigations. From a clinical perspective, all probable and confirmed cases should be treated. The choice of treatment and its duration must be considered, along with the affected organs, process severity, history of previous treatment failure, possibility of administering oral medication, associated diseases, pregnancy, and patient compliance with the proposed treatment regimen. Nevertheless, even after appropriate treatment, there may be relapses, which generally occur 5 years after the apparent cure following treatment, and also, the mycosis may be confused with other diseases. This review provides a comprehensive and critical overview of the immunopathology, laboratory diagnosis, clinical aspects, and current treatment of PCM, highlighting current issues in the identification, treatment, and patient follow-up in light of recent Paracoccidioides species taxonomic developments.


Subject(s)
Paracoccidioides , Paracoccidioidomycosis , Humans , Paracoccidioidomycosis/diagnosis , Paracoccidioidomycosis/drug therapy , Paracoccidioidomycosis/epidemiology , Brazil , Skin
6.
J Antimicrob Chemother ; 78(3): 817-822, 2023 03 02.
Article in English | MEDLINE | ID: mdl-36702754

ABSTRACT

OBJECTIVES: To evaluate the in vitro activity of isavuconazole on 154 clinical and reference strains of Trichosporon asahii, Trichosporon asteroides, Trichosporon coremiiforme, Trichosporon faecale and Trichosporon inkin by using the EUCAST broth microdilution method (BMD) and Liofilchem MIC Test Strips (MTS). METHODS: Antifungal susceptibility testing for isavuconazole, fluconazole, voriconazole and posaconazole was assessed by EUCAST E.DEF 7.3.2. MIC values of isavuconazole obtained by BMD after 48 h of incubation were compared with MTS MICs after 24 and 48 h of incubation. RESULTS: T. asahii and T. asteroides showed the highest isavuconazole MIC90 values (0.5 mg/L). In clinical isolates, T. asahii exhibited the highest MIC90 values (0.5 mg/L) compared with non-T. asahii (0.06-0.25 mg/L). The five non-WT T. asahii isolates for fluconazole, voriconazole and posaconazole also exhibited high MICs of isavuconazole (≥0.5 mg/L). A better correlation between MTS and BMD MICs was observed after 24 h incubation for all species tested. MTS measurements performed at 48 h increased by at least 122% the number of isolates with >2 dilutions compared with the standard method. CONCLUSIONS: Isavuconazole exhibited variable in vitro activity among the Trichosporon species tested, showing higher or equal MICs than the other azoles. The five non-WT T. asahii clinical isolates tested also exhibited high isavuconazole MICs, suggesting the occurrence of triazole cross-resistance. Our MTS data indicate that there is no advantage in extended reading time for MTS from 24 to 48 h for Trichosporon yeasts.


Subject(s)
Antifungal Agents , Trichosporon , Voriconazole , Fluconazole , Triazoles , Microbial Sensitivity Tests
7.
J Antimicrob Chemother ; 78(6): 1488-1494, 2023 06 01.
Article in English | MEDLINE | ID: mdl-37100456

ABSTRACT

OBJECTIVES: Although perceived as a rare clinical entity, recent studies have noted the emergence of MDR C. parapsilosis (MDR-Cp) isolates from single patients (resistant to both azole and echinocandins). We previously reported a case series of MDR-Cp isolates carrying a novel FKS1R658G mutation. Herein, we identified an echinocandin-naive patient infected with MDR-Cp a few months after the previously described isolates. WGS and CRISPR-Cas9 editing were used to explore the origin of the new MDR-Cp isolates, and to determine if the novel mutation confers echinocandin resistance. METHODS: WGS was applied to assess the clonality of these isolates and CRISPR-Cas9 editing and a Galleria mellonella model were used to examine whether FKS1R658G confers echinocandin resistance. RESULTS: Fluconazole treatment failed, and the patient was successfully treated with liposomal amphotericin B (LAMB). WGS proved that all historical and novel MDR-Cp strains were clonal and distant from the fluconazole-resistant outbreak cluster in the same hospital. CRISPR-Cas9 editing and G. mellonella virulence assays confirmed that FKS1R658G confers echinocandin resistance in vitro and in vivo. Interestingly, the FKS1R658G mutant showed a very modest fitness cost compared with the parental WT strain, consistent with the persistence of the MDR-Cp cluster in our hospital. CONCLUSIONS: Our study showcases the emergence of MDR-Cp isolates as a novel threat in clinical settings, which undermines the efficacy of the two most widely used antifungal drugs against candidiasis, leaving only LAMB as a last resort. Additionally, surveillance studies and WGS are warranted to effectively establish infection control and antifungal stewardship strategies.


Subject(s)
Antifungal Agents , Candidemia , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida parapsilosis/genetics , Fluconazole/pharmacology , Drug Resistance, Fungal , Echinocandins/pharmacology , Echinocandins/therapeutic use , Candidemia/drug therapy , Candidemia/epidemiology , Microbial Sensitivity Tests
8.
Med Mycol ; 61(2)2023 Feb 03.
Article in English | MEDLINE | ID: mdl-36694950

ABSTRACT

Invasive fungal infections caused by non-albicans Candida species are increasingly reported. Recent advances in diagnostic and molecular tools enabled better identification and detection of emerging pathogenic yeasts. The Candida haemulonii species complex accommodates several rare and recently described pathogenic species, C. duobushaemulonii, C. pseudohaemulonii, C. vulturna, and the most notorious example is the outbreak-causing multi-drug resistant member C. auris. Here, we describe a new clinically relevant yeast isolated from geographically distinct regions, representing the proposed novel species C. khanbhai, a member of the C. haemulonii species complex. Moreover, several members of the C. haemulonii species complex were observed to be invalidly described, including the clinically relevant species C. auris and C. vulturna. Hence, the opportunity was taken to correct this here, formally validating the names of C. auris, C. chanthaburiensis, C. konsanensis, C. metrosideri, C. ohialehuae, and C. vulturna.


Although C. albicans remains the major pathogenic yeast, other previously rare or even novel species are on the rise in the clinic. The most notorious example is the rapid global emergence of multidrug-resistant C. auris. Here we describe its novel sibling species C. khanbhai.


Subject(s)
Candidiasis , Invasive Fungal Infections , Animals , Candidiasis/microbiology , Candidiasis/veterinary , Saccharomyces cerevisiae , Candida/genetics , Invasive Fungal Infections/veterinary , Antifungal Agents
9.
Mycoses ; 66(9): 774-786, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37169736

ABSTRACT

BACKGROUND: In-house real-time PCR (qPCR) is increasingly used to diagnose the so-called endemic mycoses as commercial assays are not widely available. OBJECTIVES: To compare the performance of different molecular diagnostic assays for detecting Histoplasma capsulatum and Coccidioides spp. in five European reference laboratories. METHODS: Two blinded external quality assessment (EQA) panels were sent to each laboratory that performed the analysis with their in-house assays. Both panels included a range of concentrations of H. capsulatum (n = 7) and Coccidioides spp. (n = 6), negative control and DNA from other fungi. Four laboratories used specific qPCRs, and one laboratory a broad-range fungal conventional PCR (cPCR) and a specific cPCR for H. capsulatum with subsequent sequencing. RESULTS: qPCR assays were the most sensitive for the detection of H. capsulatum DNA. The lowest amount of H. capsulatum DNA detected was 1-4 fg, 0.1 pg and 10 pg for qPCRs, specific cPCR and broad-range cPCR, respectively. False positive results occurred with high concentrations of Blastomyces dermatitidis DNA in two laboratories and with Emergomyces spp. in one laboratory. For the Coccidioides panel, the lowest amount of DNA detected was 1-16 fg by qPCRs and 10 pg with the broad-range cPCR. One laboratory reported a false positive result by qPCR with high load of Uncinocarpus DNA. CONCLUSION: All five laboratories were able to correctly detect H. capsulatum and Coccidioides spp. DNA and qPCRs had a better performance than specific cPCR and broad-range cPCR. EQAs may help standardise in-house molecular tests for the so-called endemic mycoses improving patient management.


Subject(s)
Coccidioidomycosis , Histoplasmosis , Mycoses , Humans , Histoplasmosis/diagnosis , Coccidioidomycosis/diagnosis , Histoplasma/genetics , Real-Time Polymerase Chain Reaction/methods , Coccidioides/genetics , Multicenter Studies as Topic
10.
Mycopathologia ; 188(3): 243-249, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37067663

ABSTRACT

Trichosporon asteroides is an emerging yeast-like pathogen commonly misidentified by commercial biochemical identification systems. We evaluated the performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the identification of 21 clinical T. asteroides strains using the Bruker Daltonics database (BDAL) and an in-house developed library. Mass spectra were obtained by the FlexControl system v.3.4, and characterizations were performed in the Biotyper BDAL database v.4.1 and the developed in-house library. Species identification for T. asteroides failed as all 21 strains were misidentified as T. japonicum (log-scores 1.89-2.19). Extending the existing database was crucial to achieving 100% correct species-level identification and accurate distinction between species. Our results indicate that the commercial BDAL database has no discriminatory power to distinguish between T. japonicum and T. asteroides. Whereas improvement of the current BDAL database is pending, we strongly advise system users not to exclude the possibility of the failure to report T. asteroides.


Subject(s)
Mycological Typing Techniques , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Trichosporon , Trichosporonosis , Humans , Databases, Factual , Species Specificity , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Trichosporon/classification , Trichosporon/isolation & purification , Trichosporonosis/diagnosis , Trichosporonosis/microbiology , Mycological Typing Techniques/methods
11.
Mycopathologia ; 188(1-2): 129-133, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36633737

ABSTRACT

Paracoccidioidomycosis (PCM) defines a broad spectrum of human and animal diseases caused by Paracoccidioides species (Onygenales). In the twenty-first century, Paracoccidioides advanced from a monotypic taxon to a genus that harbors seven species, including P. brasiliensis sensu stricto, P. americana, P. restrepiensis, P. venezuelensis, P. lutzii, P. loboi, and P. cetii. Classic PCM, acquired upon inhalation of propagules from P. brasiliensis sensu stricto, P. americana, P. restrepiensis, P. venezuelensis, and P. lutzii, affects the human lungs and may progress to systemic granulomatous disease with tegumentary and visceral involvement. On the other hand, PCM loboi and PCM ceti caused by the unculturable P. loboi and P. cetii are subcutaneous mycoses, typically observed as keloid lesions in humans and dolphins. Such heterogeneity highlights the importance of recognizing species boundaries in Paracoccidioides to gain insights into the ecology, evolution, clinical features, and mitigation strategies to tackle the advance of PCM.


Subject(s)
Paracoccidioides , Paracoccidioidomycosis , Animals , Humans , Dolphins/microbiology , Genomics , Paracoccidioides/classification , Paracoccidioides/genetics , Paracoccidioides/isolation & purification , Paracoccidioidomycosis/diagnosis , Paracoccidioidomycosis/epidemiology , Paracoccidioidomycosis/immunology , Paracoccidioidomycosis/microbiology , Phylogeny
12.
Mycoses ; 65(3): 303-311, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34821412

ABSTRACT

Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.


Subject(s)
Fungicides, Industrial , One Health , Animals , Antifungal Agents/pharmacology , Aspergillus fumigatus , Azoles/pharmacology , Drug Resistance, Fungal , Fungicides, Industrial/pharmacology , Humans , Microbial Sensitivity Tests
13.
Mycoses ; 65(12): 1146-1158, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35869803

ABSTRACT

INTRODUCTION: Chromoblastomycosis is a disease caused by melanized fungi, primarily belonging to the genera Fonsecaea and Cladophialophora, mainly affecting individuals who are occupationally exposed to soil and plant products. This research aimed to determine the clinical, epidemiological and laboratory characteristics of chromoblastomycosis in the state of Mato Grosso, Brazil. MATERIALS AND METHODS: Patients diagnosed with chromoblastomycosis treated at the Júlio Müller University Hospital, Cuiabá, Brazil, from January 2015 to December 2020, whose isolates were preserved in the Research Laboratory of the Faculty of Medicine of the Federal University of Mato Grosso. Isolates were identified by partly sequencing the Internal Transcribed Spacer (ITS) and ß-tubulin (BT2) loci. AFLP fingerprinting was used to explore the genetic diversity. Susceptibility to itraconazole, voriconazole, 5-fluorocytosine, terbinafine and amphotericin B was determined by the broth microdilution technique. RESULTS: Ten patients were included, nine were male (mean age = 64.1 years). Mean disease duration was 8.6 years. Lesions were mainly observed in the lower limbs. Predominant clinical forms were verrucous and scarring. Systemic arterial hypertension and type II diabetes mellitus were the predominant comorbidities. Leprosy was the main concomitant infectious disease. Fonsecaea pedrosoi was the unique aetiological agent identified with moderate genetic diversity (H = 0.3934-0.4527; PIC = 0.3160-0.3502). Antifungal agents with the highest activity were terbinafine, voriconazole and itraconazole. CONCLUSION: Chromoblastomycosis is affecting the poor population in rural and urban areas, mainly related to agricultural activities, with F. pedrosoi being the dominant aetiologic agent. All isolates had low MICs for itraconazole, voriconazole and terbinafine, confirming their importance as therapeutic alternatives for chromoblastomycosis.


Subject(s)
Chromoblastomycosis , Diabetes Mellitus, Type 2 , Humans , Middle Aged , Chromoblastomycosis/drug therapy , Chromoblastomycosis/epidemiology , Chromoblastomycosis/microbiology , Itraconazole/pharmacology , Itraconazole/therapeutic use , Terbinafine/therapeutic use , Voriconazole/therapeutic use , Molecular Epidemiology , Brazil/epidemiology , Amplified Fragment Length Polymorphism Analysis , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use
14.
Mycopathologia ; 187(4): 417-420, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35536527

ABSTRACT

Diutina catenulata is an ascomycetous yeast, that is regularly fluconazole-resistant and increasingly reported as the cause of invasive infection in humans. Here, we describe the de novo genome assembly of the clinical D. catenulata type-strain CBS565 and provide insights into the genome and compared it to an Illumina-sequenced environmental strain.


Subject(s)
Nanopores , Saccharomycetales , Fluconazole , High-Throughput Nucleotide Sequencing , Humans , Saccharomycetales/genetics , Sequence Analysis, DNA
15.
Mycopathologia ; 187(4): 407-411, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35776287

ABSTRACT

Sporothrix (order Ophiostomatales) comprises a genus with 53 species, of which S. brasiliensis, S. schenckii, S. globosa, and S. luriei cause skin infections in humans and other mammals. Remarkably, closely related Sporothrix can follow different strategies in epidemics. For example, during the cat-transmitted sporotrichosis, there is an increased prevalence of the highly virulent S. brasiliensis in South America, whereas S. schenckii and S. globosa are generally associated with a sapronotic route worldwide. Therefore, species-specific types of transmission may require distinct public health strategies to mitigate the advance of sporotrichosis, including early diagnosis, isolation of new animal cases, administration of adequate antifungal therapy, and population education on the main aspects of the disease. Here, we shed light on the system Sporothrix-sporotrichosis covering hot topics in the epidemiology and diagnosis of this important neglected disease.


Subject(s)
Sporothrix , Sporotrichosis , Animals , Humans , Mammals , South America , Sporotrichosis/diagnosis , Sporotrichosis/drug therapy , Sporotrichosis/epidemiology
16.
Mycopathologia ; 187(4): 363-374, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35764905

ABSTRACT

Chromoblastomycosis and leprosy are chronic diseases with high prevalence in tropical and subtropical regions. Brazil is one of the countries with the highest incidence and prevalence for both diseases, however, reports of co-infections are scarce. The aim of this study was to describe three cases of chromoblastomycosis-leprosy co-infection in patients from Mato Grosso state, Brazil. A review of chromoblastomycosis-leprosy co-infection was performed of English, Portuguese and Spanish publications in LILACS, SciELO, PubMed and Web of Science databases using the descriptors (chromoblastomycosis OR cromoblastomicose OR cromoblastomicosis) AND (leprosy OR hanseníase OR lepra), without time period delimitation. Nineteen cases were included, 16 cases were published in 11 articles, plus the three cases reported in the current study. Most reported coninfection cases came from Brazil. Majority of the patients were male with a mean age of 52.2 years. Farmer was the main occupational activity reported. In 12 patients, the clinical signs and symptoms of leprosy started first. No contacts with patients affected by leprosy, armadillos or history of injuries at the anatomical site of chromoblastomycosis lesions were reported. Five leprosy patients who received steroid treatment for leprosy reactions or neuropathies, were diagnosed with chromoblastomycosis during immunosuppressive therapy. Four cases (21.1%) were reported among the elderly patients. Co-infections in patients with chromoblastomycosis or leprosy are uncommon, but the possibility should always be considered, especially if the patient is undergoing immunosuppressive treatment or is elder.


Subject(s)
Chromoblastomycosis , Coinfection , Leprosy , Aged , Brazil/epidemiology , Chromoblastomycosis/diagnosis , Chromoblastomycosis/drug therapy , Chromoblastomycosis/epidemiology , Coinfection/diagnosis , Coinfection/epidemiology , Female , Humans , Incidence , Leprosy/epidemiology , Male , Middle Aged
17.
Mycopathologia ; 187(1): 103-111, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34762221

ABSTRACT

Cryptococcosis is an infection caused by encapsulated basidiomycetous yeasts belonging to the Cryptococcus neoformans/Cryptococcus gattii species complexes. It is acquired through inhalation of infectious propagules, often resulting in meningitis and meningoencephalitis. The ecological niche of these agents is a wide variety of trees species, as well as pigeon, parrot and passerine excreta. The objective of this study was to isolate Cryptococcus yeasts from excreta of commercially traded parrots and passerines. The 237 samples were collected between October 2018 and April 2019 and processed using conventional methodologies. Nineteen colonies with a dark brown phenotype, caused by phenol oxidase activity, were isolated, suggesting the presence of pathogenic Cryptococcus yeasts. All isolates tested positive for urease activity. URA5-RFLP fingerprinting identified 14 isolates (68.4%) as C. neoformans (genotype AFLP1/VNI) and 5 (26.3%) as C. deuterogattii (genotype AFLP6/VGII). Multi-locus sequence typing was applied to investigate the relatedness of the C. deuterogattii isolates with those collected globally, showing that those originating from bird-excreta were genetically indistinguishable from some clinical isolates collected during the past two decades.


Subject(s)
Cryptococcosis , Cryptococcus gattii , Cryptococcus neoformans , Antifungal Agents , Cryptococcosis/veterinary , Cryptococcus gattii/genetics , Cryptococcus neoformans/genetics , Genotype , Humans , Multilocus Sequence Typing , Mycological Typing Techniques
18.
J Clin Microbiol ; 59(4)2021 03 19.
Article in English | MEDLINE | ID: mdl-33536293

ABSTRACT

Non-albicans Candida species are emerging in the nosocomial environment, with the multidrug-resistant (MDR) species Candida auris being the most notorious example. Consequently, rapid and accurate species identification has become essential. The objective of this study was to evaluate five commercially available chromogenic media for the presumptive identification of C. auris Two novel chromogenic formulations, CHROMagar Candida Plus (CHROMagar) and HiCrome C. auris MDR selective agar (HiMedia), and three reference media, CandiSelect (Bio-Rad), CHROMagar Candida (CHROMagar), and Chromatic Candida (Liofilchem), were inoculated with a collection of 9 genetically diverse C. auris strains and 35 strains from closely related comparator species. After 48 h of incubation, the media were evaluated for their ability to detect and identify C. auris All media had the same limitations in the differentiation of the more common species Candida dubliniensis and Candida glabrata Only on CHROMagar Candida Plus did C. auris colonies develop a species-specific coloration. Nevertheless, the closely related pathogenic species Candida pseudohaemulonii and Candida vulturna developed a similar appearance as C. auris on this medium. CHROMagar Candida Plus was shown to be superior in the detection and identification of C. auris, with 100% inclusivity for C. auris compared to 0% and 33% for the reference media and HiCrome C. auris MDR selective agar, respectively. Although C. vulturna and C. pseudohaemulonii can cause false positives, CHROMagar Candida Plus was shown to be a valuable addition to the plethora of mostly molecular methods for C. auris detection and identification.


Subject(s)
Candida , Chromogenic Compounds , Culture Media , Humans , Saccharomycetales , Species Specificity
19.
J Antimicrob Chemother ; 76(2): 418-422, 2021 01 19.
Article in English | MEDLINE | ID: mdl-33175162

ABSTRACT

BACKGROUND: Echinocandin resistance rarely occurs in clinical Candida parapsilosis isolates and the underlying mechanism is unknown. OBJECTIVES: To determine the prevalence of echinocandin resistance and the underlying mechanism for a large collection of C. parapsilosis blood isolates and to determine whether the echinocandin-resistant isolates were clonally related. METHODS: C. parapsilosis blood isolates (n = 213) were subjected to antifungal susceptibility testing (CLSI M27), for micafungin, anidulafungin, amphotericin B and, if appropriate, caspofungin. Hotspot (HS) 1 and HS2 of FKS1 were sequenced for all isolates (n = 213) and microsatellite typing was performed for echinocandin-resistant isolates. RESULTS: All isolates were susceptible to amphotericin B and two isolates were intermediate to anidulafungin (MIC = 4 mg/L), while micafungin resistance was noted in four isolates (MIC >8 mg/L); three of which were also fluconazole resistant and therefore were MDR. Interestingly, micafungin-resistant isolates, but not those intermediate to anidulafungin, carried novel mutation R658G in HS1 of Fks1p; three of which also harboured Y132F+K143R in Erg11. The first isolate (MICR1) was recovered in November 2017 from a patient admitted to paediatric gastroenterology who showed therapeutic failure under caspofungin treatment. MICR2-MICR4 were collected during 2018-19 and were recovered from three echinocandin-naive paediatric-surgery patients; the isolates shared the same genotype. CONCLUSIONS: Herein, for the first time (to the best of our knowledge), we identified micafungin-resistant C. parapsilosis blood isolates harbouring a novel mutation in HS1 of FKS1, which was likely attributable to in vitro micafungin resistance and in vivo caspofungin therapeutic failure. The acquisition of micafungin-resistant C. parapsilosis isolates in echinocandin-naive patients likely implicates clonal expansion, as supported by the close genetic relatedness of MICR2-MICR4.


Subject(s)
Antifungal Agents , Candida parapsilosis , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Child , Drug Resistance, Fungal , Echinocandins/pharmacology , Humans , Micafungin/pharmacology , Microbial Sensitivity Tests , Mutation
20.
Med Mycol ; 60(1)2021 Dec 08.
Article in English | MEDLINE | ID: mdl-34637525

ABSTRACT

Chromoblastomycosis is a chronic disease caused by melanized fungi that mainly affect individuals performing soil-related labor. The objective of this study was to analyze the epidemiological and clinical characteristics of chromoblastomycosis in Latin America and the Caribbean by an extensive literature review. An integrative review was performed of English, French, Portuguese, and Spanish publications in LILACS, SciELO, PubMed, SCOPUS and Web of Science databases covering the period 1969-2019. A total of 1211 articles were identified, of which 132 were included in the review, covering 2081 patients, 80.3% were males, the mean age was 56.1 years. The mean duration of the disease was 10.8 years. The lesions were mainly described in the lower limbs (60%). The most frequent clinical forms were verrucous (46.4%) and tumorous (21.7%). Major disease symptoms and signs consisted of itching and pain. Bacterial infection and functional limitation were important complications. Immunosuppression post-kidney transplantation was the most frequent comorbidity while leprosy was the main concomitant infectious disease. Fonsecaea pedrosoi and Cladophialophora carrionii were the predominant etiological agents. Majority of the cured cases were treated with itraconazole as monotherapy or in combination with other antifungals, surgery or cryosurgery. Chromoblastomycosis affects hundreds of rural workers in Latin America and the Caribbean, causing disability and personal, family and economic losses. It is important to prioritize epidemiological surveillance and early diagnosis of this disease in order to reveal its real prevalence and direct resources to preventive actions, diagnosis and early treatment. LAY SUMMARY: Chromoblastomycosis is a slowly progressing chronic disease caused by melanized fungi. We collected data from South America and the Caribbean covering 1969-2019, the 132 articles included 2081 patients, mean disease duration was 10.8 years. Fonsecaea pedrosoi and Cladophialophora carrionii predominated.


Subject(s)
Chromoblastomycosis , Animals , Antifungal Agents/therapeutic use , Caribbean Region , Chromoblastomycosis/drug therapy , Chromoblastomycosis/epidemiology , Chromoblastomycosis/veterinary , Itraconazole , Latin America/epidemiology , Male
SELECTION OF CITATIONS
SEARCH DETAIL